Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.

Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A.

Drug Metab Dispos. 2002 May;30(5):595-601.

PMID:
11950793
2.

Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression.

Crespi CL, Fox L, Stocker P, Hu M, Steimel DT.

Eur J Pharm Sci. 2000 Nov;12(1):63-8.

PMID:
11121734
3.

Detection and characterization of novel polymorphisms in the CYP2E1 gene.

Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day CP, Crespi CL, Daly AK.

Pharmacogenetics. 1998 Dec;8(6):543-52.

PMID:
9918138
4.
5.

Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.

Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JT, Gelboin HV, Gonzalez FJ, Idle JR, Daly AK.

Pharmacogenetics. 1995 Aug;5(4):234-43.

PMID:
8528270
6.

A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing.

Crespi CL, Gonzalez FJ, Steimel DT, Turner TR, Gelboin HV, Penman BW, Langenbach R.

Chem Res Toxicol. 1991 Sep-Oct;4(5):566-72.

PMID:
1793807
7.
8.

Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1.

Crespi CL, Penman BW, Leakey JA, Arlotto MP, Stark A, Parkinson A, Turner T, Steimel DT, Rudo K, Davies RL, et al.

Carcinogenesis. 1990 Aug;11(8):1293-300.

PMID:
2117502
9.

Supplemental Content

Loading ...
Support Center